SDCCAG10 Inhibitors

SDCCAG10 inhibitors encompass a diverse array of compounds that indirectly attenuate the protein's function by targeting the spliceosome, a complex molecular machine involved in the critical process of RNA splicing in which SDCCAG10 participates. These inhibitors, such as a certain cyclophilin inhibitor, effectively bind to and inactivate cyclophilins, which are integral to the proper assembly and function of the spliceosome. The inhibition of these cyclophilins ultimately impairs spliceosome assembly, thereby reducing the functional contribution of SDCCAG10 in the splicing process. Other inhibitors in this category act by disrupting the function of specific complexes within the spliceosome, such as the SF3b complex or the U2 snRNP, thereby hampering spliceosome assembly and function. The compromised spliceosome machinery fails to properly incorporate SDCCAG10, which is pivotal for the accurate splicing of pre-mRNA, thereby inhibiting its function.

Furthermore, certain inhibitors target the mTOR signaling pathway, which is known to influence the assembly of the spliceosome and thus can indirectly affect the role of SDCCAG10. The inhibitory actions of these compounds on mTOR signaling may lead to alterations in spliceosome dynamics, affecting the incorporation of SDCCAG10 into the spliceosome and its associated splicing activities. Additionally, specific bioflavonoids and adenosine analogs disrupt RNA polymerase function and splicing factor activity, further influencing spliceosome assembly and function.